Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Single or repetitive intravenous infusion(s) of BT524, depending on the severity of the disorder, location and extent of the bleeding and patient's clinical condition. Dosage based on individual body weight and fibrinogen level.”In the company’s words, NCT02065882 on ClinicalTrials.gov
- Tested for
- Congenital Afibrinogenemia, Congenital Hypofibrinogenemia, Bleeding Disorder, Hypofibrinogenemia; Acquired
- Main trialPhase 3
- “This was a prospective, open-label, multicenter, phase I/III study investigating the 14-day single-dose pharmacokinetic and pharmacodynamic properties, efficacy and safety of BT524 following intravenous administration in the treatment or prophylaxis of bleeding in patients with congenital afibrinogenemia or severe congenital hypofibrinogenemia.”In the company’s words, NCT02065882 on ClinicalTrials.gov
- Other names
- Human Fibrinogen Concentrate
Other drugs for Congenital Afibrinogenemia
- Fibrinogen ConcentrateCSL Behring · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 18 May 2020 | Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency | |
| Phase 3Completed | 25 Sep 2023 | Adjusted Fibrinogen Replacement Strategy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026